Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial

BACKGROUND: There is an on-going debate whether 2- or 3-weekly administration of R-CHOP is the preferred first-line treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL). The UK NCRI R-CHOP14v21 randomized phase 3 trial did not demonstrate a difference in outcomes between R-CHOP-...

Descripción completa

Detalles Bibliográficos
Autores principales: Kühnl, A., Cunningham, D., Counsell, N., Hawkes, E. A., Qian, W., Smith, P., Chadwick, N., Lawrie, A., Mouncey, P., Jack, A., Pocock, C., Ardeshna, K. M., Radford, J., McMillan, A., Davies, J., Turner, D., Kruger, A., Johnson, P. W., Gambell, J., Rosenwald, A., Ott, G., Horn, H., Ziepert, M., Pfreundschuh, M., Linch, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815562/
https://www.ncbi.nlm.nih.gov/pubmed/28398499
http://dx.doi.org/10.1093/annonc/mdx128

Ejemplares similares

Ejemplares similares